
    
      This is a multicentre, placebo-controlled, double-blind, 1:1 randomised Phase IIb study in
      female hormone receptor-positive metastatic breast cancer patients. The study comprises of
      two stages.

      Stage 1 is the open-label, safety run-in stage consisting of cohort 1 and 2 to confirm the
      (RPTD) of IMP321 in combination with paclitaxel.

      Stage 2 is placebo-controlled, double-blind randomisation stage, paclitaxel + IMP321 at the
      RPTD will be compared to paclitaxel + placebo.
    
  